PolyPid Ltd. (NASDAQ:PYPD) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of PolyPid Ltd. (NASDAQ:PYPD) have been given a consensus rating of “Moderate Buy” by the six ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $12.25.

A number of research firms recently commented on PYPD. Wall Street Zen raised PolyPid from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of PolyPid in a research report on Monday, December 29th. Roth Mkm dropped their price objective on shares of PolyPid from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Thursday, November 13th. Finally, Citigroup reiterated a “market outperform” rating on shares of PolyPid in a research note on Monday, December 1st.

Hedge Funds Weigh In On PolyPid

Several institutional investors and hedge funds have recently modified their holdings of PYPD. AIGH Capital Management LLC boosted its position in PolyPid by 27.0% during the second quarter. AIGH Capital Management LLC now owns 1,194,108 shares of the company’s stock worth $4,215,000 after purchasing an additional 253,727 shares in the last quarter. Lumbard & Kellner LLC purchased a new stake in shares of PolyPid in the second quarter valued at approximately $135,000. Finally, BNP Paribas Financial Markets raised its stake in shares of PolyPid by 56.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after buying an additional 3,500 shares during the period. Institutional investors and hedge funds own 26.47% of the company’s stock.

PolyPid Price Performance

NASDAQ PYPD opened at $4.80 on Wednesday. The company has a market cap of $76.32 million, a price-to-earnings ratio of -1.61 and a beta of 1.51. The stock’s fifty day moving average price is $4.16 and its 200 day moving average price is $3.73. PolyPid has a 1 year low of $2.30 and a 1 year high of $5.05.

PolyPid (NASDAQ:PYPD) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.17. Research analysts expect that PolyPid will post -1.79 earnings per share for the current year.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.